Skip to main content
OpenTrials

Clinical trial condition

Gastro-enteropancreatic neuroendocrine tumor

Explore clinical trials studying Gastro-enteropancreatic neuroendocrine tumor. Study availability and eligibility vary by location and protocol.

46 public trials 17 recruiting studies
Refine in advanced search Browse all conditions

Gastro-enteropancreatic neuroendocrine tumor trial results

Active, not recruiting

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

NCT05050942

Conditions
Gastro-enteropancreatic Neuroendocrine Tumor, Gastro-enteropancreatic neuroendocrine tumor
Locations
  • Mayo Clinic Cancer Center (MCCC) - Phoenix Phoenix, Arizona, United States
  • UCLA Ahmanson Biological Imaging Center Santa Monica, California, United States
  • Rocky Mountain Cancer Centers - Denver - Midtown Denver, Colorado, United States
  • Mayo Clinic Hospital - Florida Jacksonville, Florida, United States
View all 86 locations
View Trial Details
Active, not recruiting

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

NCT06790706

Conditions
Adenocarcinoma, Anaplastic Thyroid Carcinomas, Carcinoid Tumor, +27 more
Locations
  • Institut de Cancerologie de l'Ouest , medical oncology department Angers, France
  • Institut Bergonié, medical oncology department Bordeaux, France
  • Hospices Civils de Lyon, Thoracic Oncology Department, Louis Pradel Hospital Bron, France
  • Centre Hospitalier Universitaire de Lille, medical oncology department Lille, France
View all 15 locations
View Trial Details
Active, not recruiting

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

NCT04711135

Conditions
Gastro-enteropancreatic neuroendocrine tumor, Gastroenteropancreatic Neuroendocrine Tumors, Neoplasms, +7 more
Locations
  • University of Kentucky Lexington, Kentucky, United States
  • Cincinnati Children's Hospital Cincinnati, Ohio, United States
  • Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States
  • Centre Léon Berard Lyon, France
View Trial Details
Active, not recruiting

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488

Conditions
Gastro-enteropancreatic Neuroendocrine Tumor, Gastro-enteropancreatic neuroendocrine tumor
Locations
  • Yale Cancer Center New Haven, Connecticut, United States
  • USF - H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
  • University of Iowa Hospitals and Clinics - Oncology Iowa City, Iowa, United States
  • University of Kentucky UK Markey Cancer Center Lexington, Kentucky, United States
View all 40 locations
View Trial Details
Active, not recruiting

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

NCT03600233

Conditions
Adenocarcinoma, Adenoma, Adenoma, Islet Cell, +21 more
Locations
  • Chang Gung Memorial Hospital, KaoHsiung Kaohsiung City, Taiwan
  • Kaohsiung Medical University Hospital Kaohsiung City, Taiwan
  • New Taipei Municipal TuCheng Hospital New Taipei City, Taiwan
  • China Medical University Hospital Taichung, Taiwan
View Trial Details
Active, not recruiting

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

NCT04919226

Conditions
Gastro-enteropancreatic neuroendocrine tumor, Neoplasms, Neoplasms by Histologic Type, +4 more
Locations
  • Stanford Cancer Center Palo Alto, California, United States
  • University of Colorado Hospital, Nuclear Medicine Aurora, Colorado, United States
  • H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View all 42 locations
View Trial Details
Completed

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

NCT05997056

Conditions
Adenoma, Adenoma, Islet Cell, Digestive System Diseases, +18 more
Locations
  • Hoag Memorial Hospital Presbyterian Newport Beach, California, United States
  • Rocky Mountain Cancer Centers Denver, Colorado, United States
  • Texas Oncology Dallas, Texas, United States
  • Medical College of Wisconsin Cancer Center Milwaukee, Wisconsin, United States
View Trial Details

Related conditions